• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

原发性皮肤CD4阳性小/中型T细胞淋巴增殖性疾病：首例报告的对强力霉素有反应的拉丁美洲病例。

Primary cutaneous CD4-positive small/medium T-cell lymphoproliferative disorder: The first-reported Latin-American case with response to doxycycline.

作者信息

Escanilla Claudio, Guavita Falla Piedad Marcela, Cevallos Carolina, Ávalos Jobet Nicolás, Bobadilla Bruneau Francisco

机构信息

Instituto Chileno de Cabeza y Cuello Santiago Chile.

Departamento de Dermatología Facultad de Medicina Universidad Nacional de Colombia Bogotá Colombia.

出版信息

Clin Case Rep. 2019 Oct 29;7(12):2405-2409. doi: 10.1002/ccr3.2454. eCollection 2019 Dec.

DOI:10.1002/ccr3.2454
PMID:31893069
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6935602/
Abstract

Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder is a provisional entity according to the last WHO-EORTC classification. The treatment of choice has not yet been defined. Local therapies have been used with variable response. Doxycycline as a main treatment option is a potential low-cost and effective alternative for this disorder.

摘要

根据世界卫生组织-欧洲肿瘤研究与治疗组织（WHO-EORTC）的最新分类，原发性皮肤CD4+小/中型T细胞淋巴增殖性疾病是一个暂定的实体。目前尚未确定其首选治疗方法。局部治疗的疗效不一。强力霉素作为主要治疗选择，是治疗该疾病的一种潜在低成本且有效的替代方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9710/6935602/732c5933078c/CCR3-7-2405-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9710/6935602/a92516e0cec7/CCR3-7-2405-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9710/6935602/f529e03fe498/CCR3-7-2405-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9710/6935602/732c5933078c/CCR3-7-2405-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9710/6935602/a92516e0cec7/CCR3-7-2405-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9710/6935602/f529e03fe498/CCR3-7-2405-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9710/6935602/732c5933078c/CCR3-7-2405-g003.jpg

相似文献

1
Primary cutaneous CD4-positive small/medium T-cell lymphoproliferative disorder: The first-reported Latin-American case with response to doxycycline.原发性皮肤CD4阳性小/中型T细胞淋巴增殖性疾病：首例报告的对强力霉素有反应的拉丁美洲病例。
Clin Case Rep. 2019 Oct 29;7(12):2405-2409. doi: 10.1002/ccr3.2454. eCollection 2019 Dec.
2
Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoproliferative disorder: Report of a case and review of the literature.原发性皮肤CD4阳性小/中型多形性T细胞淋巴增殖性疾病：1例报告并文献复习
J Cutan Pathol. 2017 Nov;44(11):944-947. doi: 10.1111/cup.13011. Epub 2017 Aug 30.
3
The Clinical Spectrum of Primary Cutaneous CD4+ Small/Medium-Sized Pleomorphic T-Cell Lymphoproliferative Disorder: An Updated Systematic Literature Review and Case Series.原发性皮肤 CD4+ 小/中体型多形性 T 细胞淋巴增生性疾病的临床谱：一项更新的系统文献回顾和病例系列。
Dermatology. 2021;237(4):618-628. doi: 10.1159/000511473. Epub 2020 Dec 16.
4
Primary cutaneous CD4+ small- to medium-sized pleomorphic T-cell lymphoma: temporary remission by oral doxycycline.原发性皮肤 CD4+ 小到中等大小多形性 T 细胞淋巴瘤：口服多西环素暂时缓解。
JAMA Dermatol. 2013 Aug;149(8):956-9. doi: 10.1001/jamadermatol.2013.4162.
5
Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior.原发性皮肤CD4阳性小/中型多形性T细胞淋巴瘤：一种具有惰性病程的克隆性T细胞淋巴增殖性疾病。
Mod Pathol. 2008 Jun;21(6):708-15. doi: 10.1038/modpathol.2008.40. Epub 2008 Feb 29.
6
Clinical features and treatment outcomes for primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: a retrospective cohort study from the Dana-Farber Cancer Institute and updated literature review.原发性皮肤CD4+小/中T细胞淋巴增殖性疾病的临床特征及治疗结果：一项来自丹娜法伯癌症研究所的回顾性队列研究及文献综述更新
Leuk Lymphoma. 2022 Dec;63(12):2832-2846. doi: 10.1080/10428194.2022.2098287. Epub 2022 Jul 21.
7
Primary cutaneous CD4 small/medium T-cell lymphoproliferative disorder in children: A case report and review of the literature.儿童原发性皮肤 CD4 小/中 T 细胞淋巴组织增生性疾病：病例报告及文献复习。
Pediatr Blood Cancer. 2022 Sep;69(9):e29862. doi: 10.1002/pbc.29862. Epub 2022 Jul 11.
8
A Case of Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorder.原发性皮肤CD4+小/中型T细胞淋巴增殖性疾病1例。
Indian J Dermatol. 2023 Sep-Oct;68(5):551-553. doi: 10.4103/ijd.ijd_855_22.
9
A Case of Primary Cutaneous CD4 Positive Small/medium T Cell Lymphoma.原发性皮肤CD4阳性小/中T细胞淋巴瘤1例。
Ann Dermatol. 2011 Feb;23(1):76-80. doi: 10.5021/ad.2011.23.1.76. Epub 2011 Feb 28.
10
Clinicopathological analysis of primary cutaneous CD4-positive small/medium pleomorphic T-cell lymphoproliferative disorder: a retrospective study of 22 patients.原发性皮肤 CD4阳性小/中体型多形性 T 细胞淋巴增生性疾病的临床病理分析：22 例回顾性研究。
Int J Dermatol. 2021 Apr;60(4):497-502. doi: 10.1111/ijd.15372. Epub 2020 Dec 28.

引用本文的文献

1
A Rare Case of Primary Cutaneous CD4+ Small/Medium Size T-Cell Lymphoproliferative Disorder Responding to Rituximab.1例对利妥昔单抗有反应的原发性皮肤CD4+小/中等大小T细胞淋巴增殖性疾病罕见病例
Case Rep Dermatol. 2025 Apr 17;17(1):150-156. doi: 10.1159/000545747. eCollection 2025 Jan-Dec.
2
Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: a case with multiple tumors.原发性皮肤CD4⁺小/中型T细胞淋巴增殖性疾病：一例多发肿瘤病例
An Bras Dermatol. 2023 Sep-Oct;98(5):720-722. doi: 10.1016/j.abd.2022.05.008. Epub 2023 May 22.

本文引用的文献

1
Rare T-Cell Subtypes.罕见的T细胞亚型。
Cancer Treat Res. 2019;176:195-224. doi: 10.1007/978-3-319-99716-2_10.
2
Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoproliferative disorder: Where do we stand? A systematic review.原发性皮肤 CD4+ 小/中体型多形性 T 细胞淋巴增生性疾病：我们的现状如何？系统评价。
J Dtsch Dermatol Ges. 2019 Feb;17(2):123-136. doi: 10.1111/ddg.13691. Epub 2018 Dec 3.
3
Rare Cutaneous T-Cell Lymphomas.罕见皮肤 T 细胞淋巴瘤。
Hematol Oncol Clin North Am. 2019 Feb;33(1):135-148. doi: 10.1016/j.hoc.2018.08.004.
4
Doxycycline attenuates breast cancer related inflammation by decreasing plasma lysophosphatidate concentrations and inhibiting NF-κB activation.强力霉素通过降低血浆溶血磷脂酸浓度和抑制核因子κB激活来减轻乳腺癌相关炎症。
Mol Cancer. 2017 Feb 8;16(1):36. doi: 10.1186/s12943-017-0607-x.
5
Doxycycline down-regulates matrix metalloproteinase expression and inhibits NF-κB signaling in LPS-induced PC3 cells.强力霉素下调脂多糖诱导的PC3细胞中基质金属蛋白酶的表达并抑制核因子κB信号通路。
Folia Histochem Cytobiol. 2016;54(4):171-180. doi: 10.5603/FHC.a2016.0022. Epub 2016 Dec 14.
6
Doxycycline is an NF-κB inhibitor that induces apoptotic cell death in malignant T-cells.强力霉素是一种NF-κB抑制剂，可诱导恶性T细胞发生凋亡性细胞死亡。
Oncotarget. 2016 Nov 15;7(46):75954-75967. doi: 10.18632/oncotarget.12488.
7
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.《世界卫生组织淋巴组织肿瘤分类（2016年修订版）》
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.
8
Doxycycline reverses epithelial-to-mesenchymal transition and suppresses the proliferation and metastasis of lung cancer cells.强力霉素可逆转上皮-间质转化并抑制肺癌细胞的增殖和转移。
Oncotarget. 2015 Dec 1;6(38):40667-79. doi: 10.18632/oncotarget.5842.
9
Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.强力霉素对COP9信号体（CSN）去泛素化活性及弥漫性大B细胞淋巴瘤肿瘤生长的抑制作用
Oncotarget. 2015 Jun 20;6(17):14796-813. doi: 10.18632/oncotarget.4193.
10
Primary Cutaneous CD4+ Small/Medium-Sized T-Cell Lymphoma With Spontaneous Regression After Biopsy.活检后自发消退的原发性皮肤CD4+小/中型T细胞淋巴瘤
Actas Dermosifiliogr. 2015 Nov;106(9):767-8. doi: 10.1016/j.ad.2015.02.015. Epub 2015 Jun 18.